Giovanni Donadoni

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial

Andrés J.M. Ferreri, Giovanni Donadoni, Maria Giuseppina Cabras et al. · Journal of Clinical Oncology · 2015 · 121 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Risk‐tailored <scp>CNS</scp> prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab era

Andrés J.M. Ferreri, Marta Bruno‐Ventre, Giovanni Donadoni et al. · British Journal of Haematology · 2014 · 107 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors

Vanesa Gregorc, Filippo de Braud, Tommaso Martino De Pas et al. · Clinical Cancer Research · 2011 · 54 citations

Medicine, Oncology, Pharmacology +17

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

Vanesa Gregorc, Giovanni Citterio, Giordano Vitali et al. · European Journal of Cancer · 2009 · 53 citations

Medicine, Oncology, Pharmacology +15

High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial

Andrés J.M. Ferreri, Marianna Sassone, Barbara Kiesewetter et al. · Annals of Oncology · 2015 · 50 citations · Full text

Medicine, Oncology, Pharmacotherapy +9